Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2017 08:30 ET | Source: Versartis

Versartis Appoints Eric Dobmeier to Board of Directors

MENLO PARK, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...
May 22, 2017 08:15 ET | Source: Versartis

Versartis Presents 3-Year Somavaratan Safety and Efficacy Data and Pediatric Program Baseline Demographics at the 19th European Congress of Endocrinology

MENLO PARK, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...
April 27, 2017 16:05 ET | Source: Versartis

Versartis Reports First Quarter 2017 Financial Results

MENLO PARK, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...
April 25, 2017 08:30 ET | Source: Versartis

Versartis Appoints Jay Stout, Ph.D., as Senior Vice President, Technical Operations

MENLO PARK, Calif., April 25, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...
March 23, 2017 08:30 ET | Source: Versartis

Versartis to Host Conference Call to Review Data from ENDO 2017 on Long-Acting Somavaratan for Growth Hormone Deficiency

Management discussion to include a review of 3-year data from VERTICAL & VISTA Trials Dr. Bradley Miller featured as a guest speaker Conference Call and webcast to be held Monday, April 3 at...
March 15, 2017 08:30 ET | Source: Versartis

Versartis Appoints Tracy Woody as Chief Commercial Officer

MENLO PARK, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...
March 02, 2017 08:30 ET | Source: Versartis

Versartis Announces Data on Long-Acting Somavaratan for Growth Hormone Deficiency to be Featured in Late-Breaker Presentation at ENDO 2017

Similar PK/PD data between US and Japanese children treated with somavaratan support using the same dose in the ongoing US and Japan Phase 3 trials MENLO PARK, Calif., March 02, 2017 (GLOBE...
March 01, 2017 16:36 ET | Source: Versartis

Versartis to Present at Cowen & Co. Annual Healthcare Conference and Barclays Global Healthcare Conference

MENLO PARK, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
February 21, 2017 16:05 ET | Source: Versartis

Versartis Reports Fourth Quarter 2016 Financial Results

MENLO PARK, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of...
January 31, 2017 08:30 ET | Source: Versartis

Versartis Promotes Joshua T. Brumm to Chief Operating Officer and Paul Westberg to Chief Business Officer

MENLO PARK, Calif., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...